Glad I chose to come to Stanford for fellowship in this wonderfully vibrant research ecosystem. So grateful to you and Stanford Cancer Institute for your support for our work.

I actively use tips learned in the in-person program which helped me frame the next 5 years, and most importantly I met some incredible women. I encourage everyone interested in IO/ tumor immunology to apply. Grateful to Society for Immunotherapy of Cancer in supporting this program!

Come to Stanford Cancer Institute for cell therapy for melanoma, the first FDA approved T-cell therapy for solids in the US! We have it here, with the team led by expert Allison Betof Warner, MD, PhD!

🧵 1/N How often should I get a #COVID19 booster vaccine? Our new article published in Nature Communications estimates benefit of different frequencies of COVID vaccines against severe disease by risk group (age, immunocompromised status). Check it out here! nature.com/articles/s4146…

Incredibly proud of our Melanoma and Cell Therapy teams at Stanford Cancer Institute. We performed the first commercial lifileucel (AMTAGVI) infusion this afternoon. We are so excited to bring this treatment for advanced melanoma to our patients! #CellTherapy #TIL (posted with consent)

The answer is NO. Here's a patient with neuroblastoma who was treated 18 years ago with GD2.CAR T cells at Baylor Center for Cell and Gene Therapy and still remains in remission. We need more of these stories. researchsquare.com/article/rs-423…

Humbled by the support for our research by WWCC Conquer Cancer, the ASCO Foundation Stanford Cancer Institute; wouldn't be here w/o my mentors/supporters EdEngleman, DavidMiklos, LipikaGoyal, Nathan Reticker-Flynn, Heather Wakelee, Dr. Patt, Linda Bosserman MD, Adeeti Ullal-Reiter Future applicant tip: establish Stanford Quantitative Sciences Unit asap

Excited to share our new study of risk of T-cell #lymphomas after #CAR therapy. 1/15 🧵 nejm.org/doi/full/10.10…

"An unparalleled educational experience, providing invaluable drug development knowledge that simply cannot be found elsewhere!" —2022-23 FDA-AACR Oncology Educational Fellow Lei Deng, MD (He/Him) Apply by August 1 to join the next class of fellows: bit.ly/3Xjen6U #AACRSciencePolicy

Dr. Barnes is bringing important dermatologic care and a new angle of research focus to the Bay Area. So proud to see her dream from medical school come to fruition. scopeblog.stanford.edu/2024/07/18/ski… Leandra A. Barnes, MD, FAAD (she/her)

Here we go!! The second ever solid tumor cell therapy Tecelra (afami-cel) was approved today by FDA Oncology! Our team at Stanford Cancer Institute is thrilled to be an authorized treatment center for this first in class agent for synovial sarcoma. Approval for TILs and TCRs 6 months

Columbia welcomes CAR-T pioneer Michel Sadelain, MD, PhD, as the inaugural director of the new Columbia Initiative for Cell Engineering and Therapy and director of the Cancer Cell Therapy Initiative at the Herbert Irving Comprehensive Cancer Center. ➡️columbiamed.link/3zCR9iI

Day 1 of the Stanford Immune Therapies & irAE Biorepository. We are up and running!! Collected and processed our first sample and now off to the races - may the science begin 🐎🏁🧬 With Allison Betof Warner, MD, PhD and Elizabeth Park 💙

SF City Hall even more beautiful when it is lit up blue for #ColorectalCancerAwarenessMonth 🙏🏻 A beautiful evening of remembering loved ones and a call to action 💙🩵 An incredible event by UCSF Helen Diller Family Comprehensive Cancer Ctr, COLONTOWN, San Francisco Cancer Initiative, & Cheeky Charity #45isTheNew50 #BlueForCRC

Thnx Pauline Funchain! Presented tough GI cases #nosoftballs to a phenomenal expert panel of Bay area med onc, surg onc, and rad onc reviewing new U.S. FDA approvals & lots of new trials Stanford Cancer Institute. The science leading to these advancements MUST continue #FundtheNIH #SaveMedicaid

Reminder there's a black box warning for giving EPO to patients with cancer. This work elucidates why: EPO receptors on tumor associated macrophages play an immunoregulatory role in HCC. If the anemia isn't bad, potential target for combination IO! Congrats David + team!

With cancer rates increasing in new SEER data, NIH Funding should be INCREASED 40% given the ROI is $2.56 for every tax$ spent on discovery research. Perhaps equity/royalities back to taxpayers/govt can fund this proposal. Pts need both scientific & public health advancements.